[en] Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease-defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. This rating was mainly based on a retrospective analysis comprising patients from several large clinical trials, which, however, included only 21 patients treated with allogeneic stem cell transplantation (alloSCT). Therefore, the European Society for Blood and Marrow Transplantation performed a registry study on a larger cohort to evaluate the role of alloSCT in t(8;16) AML. Sixty transplant recipients with t(8;16) AML were identified. Two-year overall and leukemia-free survival (OS/LFS) was 43/39%. Patients transplanted in first complete remission (CR1, n = 44) achieved a 2-year OS/LFS of 48%/48%. Following alloSCT in CR1, the multivariable analysis identified a complex karyotype (CK) as a major risk factor for relapse (HR 4.17, p = .016), lower LFS (HR 3.38, p = .01), and lower OS (HR 3.08, p = .017). Two-year OS/LFS of patients with CK was 19%/19%, in contrast to 67%/67% in patients with t(8;16) outside a CK. Other factors for inferior outcomes were older age and secondary AML. In summary, alloSCT could mitigate the adverse risk of patients with t(8;16) AML not harboring a CK, particularly when performed in CR1.
Disciplines :
Hematology
Author, co-author :
Schmälter, Ann-Kristin ; Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Comprehensive Cancer Center Augsburg, Augsburg, Germany ; Bavarian Cancer Research Center (BZKF), Augsburg, Germany
Labopin, Myriam; EBMT Paris Study Office, Paris, France
Versluis, Jurjen; Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
Gallego Hernanz, Maria Pilar; Hematology Department, CHU de Poitiers, Poitiers, France
Eder, Matthias; Department of Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
von dem Borne, Peter; Leiden University Hospital, BMT Centre Leiden, Leiden, The Netherlands
Socié, Gerard; Saint-Louis Hospital, BMT Unit, Paris, France
Chevallier, Patrice ; CHU Nantes, Nantes, France
Forcade, Edouard; CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France
Neubauer, Andreas; Clinic for Hematology, Oncology, Immunology, and Carreras Leukemia Center, Philipps University Marburg, Marburg, Germany
Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques
Bazarbachi, Ali ; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Bug, Gesine ; Department for Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany
Nagler, Arnon ; Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel Aviv University, Ramat Gan, Israel
Schmid, Christoph; Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Comprehensive Cancer Center Augsburg, Augsburg, Germany ; Bavarian Cancer Research Center (BZKF), Augsburg, Germany
Gervais C, Murati A, Helias C, et al. Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia. 2008;22(8):1567-1575.
Kayser S, Döhner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137-2145.
Haferlach T, Kohlmann A, Klein H-U, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23(5):934-943.
Camós M, Esteve J, Jares P, et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006;66(14):6947-6954.
Díaz-Beyá M, Navarro A, Ferrer G, et al. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia. 2013;27(3):595-603.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
Kayser S, Hills RK, Langova R, et al. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an international collaborative study*. Br J Haematol. 2021;192(5):832-842.
Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. Ann Hematol. 2019;98(5):1149-1157.
Chakraborty S, Adams J, Nassiri M, Vance GH. Therapy-related myeloid neoplasm with bone marrow involvement, myelosarcoma, and a t(8;16)(p11.2;p13.3)—a case report. Cancer Genet. 2014;207(10–12):511-515.
Diab A, Zickl L, Abdel-Wahab O, et al. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res. 2013;37(1):32-36.
Aqil B, Gao J, Stalling M, et al. Distinctive flow Cytometric and mutational profile of acute myeloid leukemia with t(8;16)(p11;p13) translocation. Am J Clin Pathol. 2022;157(5):701-708.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-611.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
Bornhäuser M, Schliemann C, Schetelig J, et al. Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2023;9(4):519-526.
Ciurea SO, Labopin M, Socie G, et al. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: a report from the acute leukemia working Party of the European Society for blood and marrow transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018;124(10):2134-2141.
Schmaelter A-K, Labopin M, Socié G, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10(3):26.
